Cancer Drug Choices Tied to Drugmaker Payouts to Doctors
April 11, 2018
(Reuters) – Some oncologists may be more likely to prescribe certain cancer medicines when they receive payments from the companies that make these drugs, a U.S. study suggests. Researchers examined data on payments drug companies made to doctors in 2013 for research funding as well general payments such as gifts, fees for speaking or consulting work, meals or travel. Then, researchers looked at how often doctors prescribed different drugs for two types of cancers with multiple treatment options: kidney cancer and a rare blood cell cancer known as chronic myeloid leukemia.